PATENT CLAIM ANALYSIS

Application Number: 16162170
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["424", "204100"]

Abstract:
The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS1 protein, wherein the vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing the influenza virus vector, its use for the treatment of cancer patients and methods for producing the influenza virus vaccine.

Claim (Index 4):
The influenza virus vector of  claim 1 , wherein the truncated NS1 protein contains up to 120 amino acids, up to 115 amino acids, up to 110 amino acids, up to 105 amino acids, up to 100 amino acids, up to 95 amino acids, preferably up to 90 amino acids, up to 85 amino acids, up to 80 amino acids, or up to 75 amino acids of the N-terminus of the respective wild type NS1 protein.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.51613
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15031715', '14049601', '15375664', '16126791', '12148798']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7207013716272382
- 35 USC 102 Novelty (BERT): 0.6076316741564904
- Combined Prediction Score: 0.7093944018801634
- Mean Citation Score: 409.569488
- Max Citation Score: 591.21484
- Similarity Product: 443.29448841176514

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test